Alpha Score of 48 reflects weak overall profile with weak momentum, weak value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Amgen Inc. shares continue to trade within the upper tier of their 52-week range of $262.28 to $388.16, reflecting market focus on the company's recent financial performance. The firm reported a significant 88.6% year-over-year increase in EPS, reaching $10.74, while revenue growth maintained a steady pace at 10.0%. These results contribute to a net margin of 21.0%, underscoring operational efficiency in the current healthcare landscape. However, the valuation remains stretched with a P/E ratio of 32.68, which aligns with the company's lower value sub-score of 44.7 within the Alpha Score framework. Overall, the Alpha Score of 51.6 is driven primarily by a quality sub-score of 66.4 and a momentum sub-score of 60.3. While the earnings expansion is notable, the current P/E suggests investors are pricing in substantial future growth expectations. The lack of sentiment data leaves the market to rely strictly on fundamental output as the primary driver for price action. Moving forward, observers should monitor whether the company can sustain its high EPS growth rate to justify the current valuation multiple throughout the remainder of the quarter.
On February 17, 2026, Amgen Inc. finalized the issuance and sale of $4 billion in aggregate principal amount of senior unsecured notes. The offering consists of four distinct tranches: $1 billion in 4.200% notes due 2031, $1.75 billion in 4.850% notes due 2036, $500 million in 5.500% notes due 2046, and $750 million in 5.650% notes due 2056. The company reported net proceeds of approximately $3.96 billion after accounting for underwriting discounts and estimated offering expenses. Interest on all notes is payable semi-annually in arrears on February 19 and August 19 of each year, with the first payment scheduled for August 19, 2026. The notes were issued under an existing indenture dated May 22, 2014, and are registered under a Form S-3 registration statement filed on February 13, 2026. The debt ranks equally with the company's existing and future senior unsecured obligations and is senior to all subordinated indebtedness. In the event of a change in control triggering event, holders have the right to require Amgen to repurchase the notes at 101% of the principal amount plus any accrued and unpaid interest. The offering was managed by a syndicate of underwriters including BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Morgan Stanley & Co.
Amgen Inc. filed its 2025 Form 10-K, providing a comprehensive overview of its financial results and operational status for the fiscal year ended December 31, 2025. The filing outlines the company's performance across its diverse product portfolio, including key assets such as Prolia, Repatha, Otezla, Enbrel, Evenity, and Xgeva. The report highlights the company's ongoing commitment to research and development, as well as its strategic collaborations with entities like AstraZeneca, UCB, and BeOne. Amgen maintains significant customer concentration, with three primary customers accounting for a substantial portion of its product sales and accounts receivable. The company continues to navigate complex tax environments across domestic and foreign jurisdictions, including operations in Ireland, Puerto Rico, and Singapore. The filing also provides details on equity-based compensation, including restricted stock units and performance units, and notes the ongoing integration of assets acquired from Horizon Therapeutics. Management continues to monitor market risks, including patent expirations, regulatory challenges, and competitive pressures in the biopharmaceutical sector.
On February 3, 2026, Amgen Inc. filed an 8-K to announce its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal notification of the release of the company's earnings press release, which is provided as an exhibit. In conjunction with its GAAP financial results, Amgen disclosed several non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, and operating expenses. The company also reported Free Cash Flow, EBITDA, and a debt leverage ratio. Amgen management stated that these non-GAAP metrics are utilized to enhance the understanding of ongoing business performance, facilitate period-over-period comparisons, and assist in internal budgeting and resource allocation. The company provided a detailed explanation of the adjustments made to reconcile GAAP figures to non-GAAP measures. These adjustments primarily exclude acquisition-related expenses, such as the amortization and impairment of intangible assets and the fair value step-up of acquired inventory. Additionally, the company excludes costs associated with restructuring and cost-savings initiatives, including severance and facility-related charges. Other excluded items include gains or losses on equity security investments and expenses related to legal proceedings deemed outside the ordinary course of business. Amgen emphasized that these non-GAAP measures are supplemental and should not be considered a substitute for GAAP financial performance metrics. The filing confirms that the information provided in the press release is furnished and not filed for the purposes of Section 18 of the Securities Exchange Act of 1934.
On January 30, 2026, Amgen Inc. filed an 8-K report announcing the formal termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd. The original agreement, which was established on June 1, 2021, governed a strategic partnership between the two pharmaceutical companies. Under the terms of the new Termination Agreement, both parties have mutually agreed to dissolve the existing arrangement. The termination is subject to customary regulatory approval, at which point the agreement will officially cease to be in effect. The filing does not disclose specific financial impacts or the underlying strategic reasons for the dissolution of the partnership. Amgen has included the Termination Agreement as an exhibit to the filing, noting that certain non-material and confidential portions have been redacted.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 1.70M | $557.60M | NEW |
| D.E. Shaw David Shaw | 164K | $53.64M | NEW |
| Marshall Wace | 99K | $32.36M | NEW |
| ARK Invest Cathie Wood | 45K | $14.85M | NEW |
| Point72 Steve Cohen | 11K | $3.67M | NEW |
| Hussman Investment Trust John Hussman | 8K | $2.75M | NEW |
Amgen Inc. is a leading biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products target serious illnesses, including Enbrel for rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for plaque psoriasis, psoriatic arthritis, and Behçet's disease oral ulcers; Prolia for postmenopausal osteoporosis; XGEVA to prevent skeletal-related events; and Repatha to reduce risks of myocardial infarction, stroke, and coronary revascularization. Additional key offerings encompass Nplate for immune thrombocytopenia, KYPROLIS for relapsed or refractory multiple myeloma, Aranesp for anemia, EVENITY for osteoporosis, Vectibix for metastatic colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic refractory gout. Amgen also markets products like Neulasta, MVASI, AMJEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI. Founded in 1980 and headquartered in Thousand Oaks, California, with approximately 28,000 employees, Amgen plays a pivotal role in the biopharmaceutical sector by addressing unmet needs in oncology, inflammation, cardiovascular disease, bone health, and rare disorders, contributing significantly to global healthcare advancements.
Earnings calendar coming soon. Subscribe to get notified when AMGN reports next.
Get earnings alerts →